Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.

https://doi.org/10.1182/hematology.2019000075

Published: 2019

Journal Articles

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist

Tanya M. Wildes, Kenneth C. Anderson

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 88–96.

https://doi.org/10.1182/asheducation-2018.1.88

Published: 2018

Journal Articles

Fixed duration vs continuous therapy in multiple myeloma

Heinz Ludwig, Niklas Zojer

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 212–222.

https://doi.org/10.1182/asheducation-2017.1.212

Published: 2017

Journal Articles

Management of multiple myeloma in the relapsed/refractory patient

Pieter Sonneveld

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 508–517.

https://doi.org/10.1182/asheducation-2017.1.508

Published: 2017

Journal Articles

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Andrew J. Yee, Noopur S. Raje

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 495–503.

https://doi.org/10.1182/asheducation-2016.1.495

Published: 2016

Journal Articles

Maintenance therapy for multiple myeloma in the era of novel agents

Thierry Facon

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 279–285.

https://doi.org/10.1182/asheducation-2015.1.279

Published: 2015

Journal Articles

Novel combination approaches for myeloma

Sagar Lonial, Ajay K. Nooka

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 286–293.

https://doi.org/10.1182/asheducation-2015.1.286

Published: 2015

Journal Articles

Treatment of hemophagocytic lymphohistiocytosis in adults

Paul La Rosée

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 190–196.

https://doi.org/10.1182/asheducation-2015.1.190

Published: 2015

Journal Articles

Balancing cure and long-term risks in acute lymphoblastic leukemia

Lewis B. Silverman

Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 190–197.

https://doi.org/10.1182/asheducation-2014.1.190

Published: 2014

Journal Articles

Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?

S. Vincent Rajkumar

Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 354–361.

https://doi.org/10.1182/asheducation.V2012.1.354.3798330

Published: 2012

Journal Articles

What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?

Emma Scott, Donna Reece

Hematology Am Soc Hematol Educ Program (2011) 2011 (1): 205–207.

https://doi.org/10.1182/asheducation-2011.1.205

Published: 2011

Journal Articles

Immune Thrombocytopenia

Adam Cuker, Douglas B. Cines

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 377–384.

https://doi.org/10.1182/asheducation.V2010.1.377.3643150

Published: 2010

Journal Articles

Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy

Adam D. Cohen, Raymond L. Comenzo

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 287–294.

https://doi.org/10.1182/asheducation-2010.1.287

Published: 2010

Journal Articles

Renal Insufficiency and Failure

Meletios A. Dimopoulos, Evangelos Terpos

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 431–436.

https://doi.org/10.1182/asheducation-2010.1.431

Published: 2010

Journal Articles

Thrombosis in Multiple Myeloma

Sigurdur Yngvi Kristinsson

Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 437–444.

https://doi.org/10.1182/asheducation-2010.1.437

Published: 2010

Journal Articles

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing

Antonio Palumbo, Francesca Gay

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 566–577.

https://doi.org/10.1182/asheducation-2009.1.566

Published: 2009

Journal Articles

ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?

Irene M. Ghobrial, A. Keith Stewart

Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 587–589.

https://doi.org/10.1182/asheducation-2009.1.587

Published: 2009

Journal Articles

Induction Therapy in Multiple Myeloma

Jean-Luc Harousseau

Hematology Am Soc Hematol Educ Program (2008) 2008 (1): 306–312.

https://doi.org/10.1182/asheducation-2008.1.306

Published: 2008

Journal Articles

Antibody Therapy in Aggressive Lymphomas

Thomas M. Habermann

Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 257–264.

https://doi.org/10.1182/asheducation-2007.1.257

Published: 2007

Journal Articles

Thrombotic Complications of Myeloma Therapy

Jeffrey A. Zonder

Hematology Am Soc Hematol Educ Program (2006) 2006 (1): 348–355.

https://doi.org/10.1182/asheducation-2006.1.348

Published: 2006

NARROW

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist

Fixed duration vs continuous therapy in multiple myeloma

Management of multiple myeloma in the relapsed/refractory patient

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Maintenance therapy for multiple myeloma in the era of novel agents

Novel combination approaches for myeloma

Treatment of hemophagocytic lymphohistiocytosis in adults

Balancing cure and long-term risks in acute lymphoblastic leukemia

Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?

What is the Benefit of Maintenance Therapy with Lenalidomide or Bortezomib after Autologous Stem Cell Transplantation in Multiple Myeloma and What is the Risk of Developing a Secondary Primary Malignancy?

Immune Thrombocytopenia

Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy

Renal Insufficiency and Failure

Thrombosis in Multiple Myeloma

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing

ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?

Induction Therapy in Multiple Myeloma

Antibody Therapy in Aggressive Lymphomas

Thrombotic Complications of Myeloma Therapy

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only